Page 3 - Denis Bedoret News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Pfizer takes equity stake in Imcyse as part of the recently announced Rheumatoid Arthritis license agreement Major existing shareholders participated in the round Proceeds to advance Imcyse’s pipeline of first-in-class targeted disease modifying immunotherapeutics Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of … Pfizer takes equity stake in Imcyse as part of the recently announced Rheumatoid Arthritis license agreement Major existing shareholders participated in the round Proceed...

DGAP-News: Imcyse Raises Additional EUR 21.3 Million in Series B Financing Round - Pfizer Joins as Newest Shareholder vom 17.02.2021, 14:00 Uhr Bild: pixabay.com DGAP-News: Imcyse SA / Key word(s): Financing Imcyse Raises Additional EUR 21.3 Million in Series B Financing Round - Pfizer Joins as Newest Shareholder 17.02.2021 / 14:00 The issuer is solely responsible for the content of this announcement. Imcyse Raises Additional EUR 21.3 Million in Series B Financing Round - Pfizer Joins as Newest Shareholder Pfizer takes equity stake in Imcyse as part of the recently announced Rheumatoid Art...

Hits: 1464 Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active, specific immunotherapies for the treatment of severe, chronic autoimmune diseases, today enters into Research Collaboration and License Agreement for its Imotope™ Technology with Pfizer in Rheumatoid Arthritis • Imcyse and Pfizer to collaborate to develop Imotope™ candidates to potentially treat Rheumatoid Arthritis  • Pfizer to lead clinical development and commercialization activities • Imcyse to receive upfront payment in cash and through the purchase of equit...

Imcyse for a rheumatoid arthritis program, which is based on that company’s Imotope technology. Pfizer will lead clinical development of the RA program. This is not the first rheumatoid arthritis deal Pfizer and Imcyse have conducted. In 2018, the companies entered into an agreement to develop an Imotope, which is a specific modified peptide that targets rheumatoid arthritis. The Imcyse Imotope platform represents what the companies believe is a next generation and potentially curative approach to severe autoimmune diseases. Imotopes are designed to induce cytolytic T cells, which specifi...

DGAP-News: Imcys ... DGAP-News: Imcyse Announces Start of Phase 1b/2a IMPACT Study in Patients with Recent Onset Type 1 Diabetes vom 03.02.2021, 14:00 Uhr Bild: pixabay.com DGAP-News: Imcyse SA / Key word(s): Study Imcyse Announces Start of Phase 1b/2a IMPACT Study in Patients with Recent Onset Type 1 Diabetes 03.02.2021 / 14:00 The issuer is solely responsible for the content of this announcement. Imcyse Announces Start of Phase 1b/2a IMPACT Study in Patients with Recent Onset Type 1 Diabetes Liège, Belgium, February 03, 2021 - Imcyse, a clinical-stage biopharmaceutical company...